Sugi Predict

Sugi Predict / Compounds / SCHEMBL1968331

SCHEMBL1968331

SCHEMBL1968331

COC(=O)[C@@H]1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ RECQL P46063 1/20 0.52
▸ EPHX1 P07099 1/20 0.52
▸ PTPN2 P17706 1/20 0.51
▸ PTPN1 P18031 1/20 0.51
▸ PTPN6 P29350 1/20 0.51
▸ STS P08842 6/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ POLB P06746 1/20 0.48
▸ ABL1 P00519 1/20 0.47
▸ RIN1 Q13671 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1119307 1.00 HPGD (0.59) HPGDSMN1; SMN2RECQLEPHX1PTPN2
SCHEMBL1973022 1.00 HPGD (0.59) HPGDSMN1; SMN2RECQLEPHX1PTPN2
SCHEMBL9882415 0.91 ALDH1A1 (0.61) HPGDSMN1; SMN2RECQLEPHX1PTPN2
SCHEMBL641371 0.91 ALDH1A1 (0.61) HPGDSMN1; SMN2RECQLEPHX1PTPN2
SCHEMBL641372 0.91 ALDH1A1 (0.61) HPGDSMN1; SMN2RECQLEPHX1PTPN2
SCHEMBL30885566 0.90 HPGD (0.62) HPGDSMN1; SMN2RECQLEPHX1PTPN2
SCHEMBL57231 0.90 HPGD (0.62) HPGDSMN1; SMN2RECQLEPHX1PTPN2
SCHEMBL18275027 0.90 HPGD (0.50) HPGDSMN1; SMN2RECQLEPHX1PTPN2
SCHEMBL23210360 0.89 HPGD (0.58) HPGDSMN1; SMN2RECQLEPHX1PTPN2
SCHEMBL8182758 0.87 HPGD (0.51) HPGDSMN1; SMN2RECQLEPHX1PTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2025-09-04 — — US disclosed
EP-4536650-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 — — EP disclosed
US-20250066386-A1 INHIBITORS OF KRAS BIOMEA FUSION, INC. 2025-02-27 — — US disclosed
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2024-08-29 — — US disclosed
EP-4408838-A1 DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES Zevra Denmark A/S (DK) 2024-08-07 — — EP disclosed
WO-2023240038-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2023-12-14 — — WO disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 — — US disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 — — US disclosed
WO-2023086341-A1 INHIBITORS OF KRAS BIOMEA FUSION, INC. (US) 2023-05-19 — — WO disclosed
WO-2023053007-A1 DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES KEMPHARM DENMARK A/S (DK) 2023-04-06 — — WO disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 — — WO disclosed
US-20090118284-A1 Novel compounds that are ERK inhibitors MERCK SHARP & DOHME LLC 2009-05-07 — — US disclosed
US-20090118284-A1 Novel compounds that are ERK inhibitors MERCK SHARP & DOHME LLC 2009-05-07 — — US disclosed
US-20070232610-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-10-04 — — US disclosed
US-20070232610-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-10-04 — — US disclosed
US-20070191604-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-08-16 — — US disclosed
US-20070191604-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-08-16 — — US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 — — US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 — — US disclosed
WO-2006041831-A2 CYCLIC Β-AMINO ACID DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066386-A1 INHIBITORS OF KRAS KRAS, NRAS, HRAS HPGD 2476/4885SMN1; SMN2 3553/4885RECQL 384/4885
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR HPGD 2557/4885SMN1; SMN2 4565/4885RECQL 444/4885
US-20090118284-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPK10 HPGD 954/4885SMN1; SMN2 3973/4885RECQL 1508/4885
US-20070191604-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPKAPK2 HPGD 954/4885SMN1; SMN2 3842/4885RECQL 1366/4885
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR HPGD 2557/4885SMN1; SMN2 4565/4885RECQL 444/4885
US-20070232610-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPKAPK2 HPGD 954/4885SMN1; SMN2 3842/4885RECQL 1366/4885
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS SREBF1, SREBF2, NR1H3 HPGD 987/4885SMN1; SMN2 4785/4885RECQL 3646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.